What this means
This is a review that pulls together earlier research on aging immune cells and cancer treatment. It says chronological age alone does not reliably predict how people respond to immunotherapy.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- A review of earlier studies, not a new test in people
- Kind of research
- A summary of earlier studies
The science
- Original title
- Tumor-associated immunosenescence: Mechanisms, biomarkers and age-adaptive immunotherapy.
- Authors
- Wu H, Yang Z, Zhang H et al.
- Journal
- Critical reviews in oncology/hematology
- Published
- Oct 12, 2026
- Study type
- Review
- PMID
- 42863771 ↗
Abstract
Immunosenescence alters immune-cell composition, signaling, metabolism, and regenerative capacity, but chronological age alone does not reliably predict response to cancer immunotherapy. In older adults, thymic involution, hematopoietic remodeling, inflammaging, and the accumulation of dysfunctional lymphoid and myeloid populations interact with tumor-derived suppressive signals. We organize these processes within an Immunosenescence-Immunotherapy Interference Axis linking systemic immune aging, local tumor remodeling, and treatment-specific vulnerabilities. Evidence is reviewed for senescence-like and exhausted CD8 + T cells, NK-cell dysfunction, age-associated macrophage states, loss of T-cell receptor diversity, and their relationship to immune checkpoint blockade. We then assess blood, tissue, and single-cell biomarkers that may distinguish biological immune age from chronological age, with particular attention to the limitations of single-marker classification. Finally, we critically evaluate senolytics, cytokine support, co-stimulatory approaches, and metabolic modulation as potential adjuncts to immunotherapy. The available evidence supports biomarker-informed, age-adaptive trial design, but prospective validation is required before immune-rejuvenation strategies can be recommended in routine oncology.
Wu H, Yang Z, Zhang H et al. Tumor-associated immunosenescence: Mechanisms, biomarkers and age-adaptive immunotherapy. Critical reviews in oncology/hematology. 2026. doi:10.1016/j.critrevonc.2026.105647. PMID: 42863771. https://pubmed.ncbi.nlm.nih.gov/42863771/
Related research
New fluorescent sensor detects cells aging from cancer and lung drugs
Researchers built a glowing probe that lights up only in certain aged cells. It may help scientists track these cells in living animals, but this is early lab work.
Mixing a senescence-clearing drug with trametinib slowed glioma regrowth in mice
Researchers found a drug combination that cleared aging-like tumour cells in mice and slowed regrowth. This does not show the combination would work the same way in children.
A vaccine-style treatment in mice eased diabetes signs and aged cell markers
Mice given a treatment aimed at a virus-like gene showed less weight gain and better blood sugar control. This study was in mice and cells, so it does not show the same would happen in people.
Aging cells that support stem cells may disrupt them through chemical signals
This is a review that pulls together older and newer studies. It proposes a model, but it does not show that the model is true.
Cx43 protein may boost breast cancer drug response in lab tests
Researchers studied a protein called Cx43 that helps cells talk to each other. They found it may help a breast cancer drug slow tumor growth. This early work is not yet checked by other scientists, so it does not show this would help people.
A new vaccine clears aging cells in mice and may extend lifespan
Researchers made a vaccine aimed at old, worn-out cells called senescent cells. In mice, it cleared some of these cells and helped metabolism. This is early work, so it does not show the vaccine would help people.
See all research on Senolytics →